Anna E. Kirkland et al.: A scoping review of the use of cannabidiol in psychiatric disorders. In: Psychiatry
Research. Band308, Februar 2022, S.114347, doi:10.1016/j.psychres.2021.114347, PMID 34952255, PMC 8799523 (freier Volltext).
↑Campos AC,
Moreira FA, Gomes FV, Del Bel EA, Guimarães FS (December 2012). "Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders".
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences (Review). 367 (1607): 3364–78. doi:10.1098/rstb.2011.0389. PMC 3481531 (freier Volltext). PMID 23108553.
↑A. W.
Zuardiet al.: Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. In: Braz. J. Med. Biol. Res. (Review) 39 (4), April 2006, S.
421–429. doi:10.1590/S0100-879X2006000400001. PMID 16612464.
↑S. Yamaori
et al.: Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. In: Life
Sci. Band88, 2011, S.730–736.
↑A. L.
Geffrey et al.: Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. In: Epilepsia. Band56, 2015, S.1246–1251.
↑Sadiye
Amcaoglu Riederet al.: Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. In: Immunobiology. Band215, Nr.8, August 2010, PMID 19457575.
↑Saphala
Dhital et al.: Cannabidiol (CBD) induces functional Tregs in response to low-level T cell activation. In: Cellular Immunology. Band312, 2017, PMID 27865421.
↑Andrenyak
DM, Moody DE, Slawson MH, O’Leary DS, Haney M: Determination of ∆-9-Tetrahydrocannabinol (THC), 11-hydroxy-THC, 11-nor-9-carboxy-THC and Cannabidiol in Human Plasma using Gas
Chromatography-Tandem Mass Spectrometry., J Anal Toxicol. 2017 May 1;41(4):277-288, PMID 28069869
↑Pigliasco
F, Barco S, Dubois S, Marchese F, Striano P, Lomonaco T, Mattioli F, Tripodi G, Cangemi G: Cannabidiol Determination on Peripheral Capillary Blood Using a Microsampling Method
and Ultra-High-Performance Liquid Chromatography Tandem Mass Spectrometry with On-Line Sample Preparation. Molecules. 2020 Aug 8;25(16):3608, PMID 32784413
↑Cliburn KD,
Huestis MA, Wagner JR, Kemp PM: Identification and quantification of cannabinoids in postmortem fluids and tissues by liquid chromatography-tandem mass spectrometry., J
Chromatogr A. 2021 Aug 30;1652:462345, PMID 34198104
↑Cobo-Golpe
M, de-Castro-Ríos A, Cruz A, López-Rivadulla M, Lendoiro E: Determination and Distribution of Cannabinoids in Nail and Hair Samples. J Anal Toxicol. 2021 Nov
9;45(9):969-97, PMID 33064813
↑Ramnarine
RS, Poklis JL, Wolf CE: Determination of Cannabinoids in Breast Milk Using QuEChERS and Ultra-Performance Liquid Chromatography and Tandem Mass Spectrometry., J Anal
Toxicol. 2019 Oct 17;43(9):746-752, PMID 31436289
↑G. Esposito
et al.: Cannabidiol in inflammatory bowel diseases: a brief overview. In: Phytotherapy research : PTR. Band 27, Nummer 5, Mai 2013,
S. 633–636, doi:10.1002/ptr.4781. PMID 22815234.
↑V. Micale
et al.: Endocannabinoid system and mood disorders: priming a target for new therapies. In: Pharmacology & therapeutics. Band 138, Nummer 1, April
2013, S. 18–37, doi:10.1016/j.pharmthera.2012.12.002. PMID 23261685.
↑D. Hermann
und M. Schneider: Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. In: Curr
Pharm Des. 18(32), 2012, S. 4897–4905. Review. PMID 22716143.
↑Dixon H. Xu
et al.: The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. In: Current Pharmaceutical
Biotechnology. 1. Dezember 2019, doi:10.2174/1389201020666191202111534, PMID 31793418.
↑D.C.
Hammell et al.: Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis.
In: European journal of pain (London, England). Band20, Nr.6, Juli
2016, S.936–948, doi:10.1002/ejp.818, PMID 26517407, PMC 4851925 (freier Volltext) – (englisch).
↑Kiffen
für Streber. In: Die Zeit. 22. Mai 2019 (zeit.de).
↑Gemeinsamer
Sortenkatalog für landwirtschaftliche Pflanzenarten gemäß Artikel 9 der Delegierten Verordnung (EU) Nr. 639/2014 der Kommission vom 11. März 2014 zur Ergänzung der Verordnung (EU) Nr.
1307/2013 des Europäischen Parlaments und des Rates mit Vorschriften über Direktzahlungen an Inhaber landwirtschaftlicher Betriebe im Rahmen von Stützungsregelungen der Gemeinsamen
Agrarpolitik und zur Änderung des Anhangs X der genannten Verordnung (ABl. L 181 vom 20.6.2014, S. 1) mit Stichtag 15. März des jeweiligen Anbaujahrs.
↑Sarah
Heuberger: Neues BGH-Urteil zu Cannabisblüten ist für Start-ups nur ein Teilerfolg. In: DIE WELT. 31. März 2021 (welt.de [abgerufen am 10. September 2021]).
↑Cannabis. Bundesamt für Gesundheit (BAG), abgerufen am 8. Juli 2023.
↑Hongkong gegen Hanfprodukt: CBD-Verbot tritt in Kraft. In: Die Tageszeitung: taz. 1. Februar 2023 (taz.de [abgerufen am 4. September 2023]).
↑A. Huestis
Marilyn, Solimini Renata, Pichini Simona, Pacifici Roberta, Carlier Jeremy: Cannabidiol Adverse Effects and Toxicity. 30. September 2019, abgerufen am 29. Juli
2021 (englisch).
↑Till
Uebelacker: CBD-Produkte: Verbraucherschützer warnen vor Nebenwirkungen. In: DIE WELT. 21. Dezember 2020 (welt.de [abgerufen am 29. Juli 2021]).
↑Penny F.
Whiting, Robert F. Wolff, Sohan Deshpande, Marcello Di Nisio, Steven Duffy: Cannabinoids for Medical Use: A Systematic Review and Meta-analysis.
In: JAMA. Band313, Nr.24, Juni 2015, S.2456–2473, doi:10.1001/jama.2015.6358, PMID 26103030.
Moltke J,
Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res. 2021;3(1):5. Published 2021 Feb
18. doi:10.1186/s42238-021-00061-5
Shannon
S, Lewis N, Lee H, Hughes S. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18-041. doi:10.7812/TPP/18-041
Bergamaschi MM,
Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology.
2011;36(6):1219-1226. doi:10.1038/npp.2011.6
Cuttler
C, Spradlin A, McLaughlin RJ. A naturalistic examination of the perceived effects of cannabis on negative affect. J Affect Disord. 2018;235:198-205. doi:10.1016/j.jad.2018.04.054
Greco R,
Gasperi V, Maccarrone M, Tassorelli C. The endocannabinoid system and migraine. Exp Neurol. 2010;224(1):85-91. doi:10.1016/j.expneurol.2010.03.029
Carlini
EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21(S1):417S-427S. doi:10.1002/j.1552-4604.1981.tb02622.x
De Vita,
M. J., Maisto, S. A., Gilmour, C. E., McGuire, L., Tarvin, E., & Moskal, D. (2021). The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy
adults: A balanced placebo design trial. Experimental and Clinical Psychopharmacology. Advance online publication. https://doi.org/10.1037/pha0000465
Tóth KF,
Ádám D, Bíró T, Oláh A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the „C(ut)annabinoid“ System. Molecules. 2019;24(5):918. Published 2019 Mar 6. doi:10.3390/molecules24050918
Jerzy P.
Szaflarski, Elizabeth Martina Bebin, Gary Cutter, Jennifer DeWolfe, Leon S. Dure, Tyler E. Gaston, Pongkiat Kankirawatana, Yuliang Liu, Rani Singh, David G. Standaert, Ashley E. Thomas,
Lawrence W. Ver Hoef, Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study, Epilepsy & Behavior, Volume 87, 2018,
Pages 131-136, ISSN 1525-5050, https://doi.org/10.1016/j.yebeh.2018.07.020.
Elizabeth
A. Thiele, Eric D Marsh, Jacqueline A French, Maria Mazurkiewicz-Beldzinska, Selim R. Benbadis, Charuta Joshi, et al., Cannabidiol in patients with seizures associated with Lennox-Gastaut
syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial, VOLUME 391, ISSUE 10125, P1085-1096, MARCH 17, 2018, https://doi.org/10.1016/S0140-6736(18)30136-3
Kunos G,
Osei-Hyiaman D, Liu J, Godlewski G, Bátkai S. Endocannabinoids and the control of energy homeostasis. J Biol Chem. 2008;283(48):33021-33025. doi:10.1074/jbc.R800012200
Bielawiec
P, Harasim-Symbor E, Chabowski A. Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol. Front Endocrinol (Lausanne). 2020;11:114. Published 2020 Mar
4. doi:10.3389/fendo.2020.00114
Morgan
CJ, Das RK, Joye A, Curran HV, Kamboj SK. Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav. 2013;38(9):2433-2436. doi:10.1016/j.addbeh.2013.03.011
Argueta
DA, Ventura CM, Kiven S, Sagi V, Gupta K. A Balanced Approach for Cannabidiol Use in Chronic Pain. Front Pharmacol. 2020;11:561. Published 2020 Apr 30. doi:10.3389/fphar.2020.00561
CANNABIDIOL (CBD), Pre-Review Report, Agenda Item 5.2, WHO
Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, 6-10 November 2017, Zugriff 06.02.2022
Kerstin
Iffland, Franjo Grotenhermen; An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies, 1 Jun 2017, https://doi.org/10.1089/can.2016.0034